Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a progressive disease and a composite endpoint could be an indicator of treatment effect on disease worsening. This post-hoc analysis assessed whether indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily reduced the risk of clinically...

Descripción completa

Detalles Bibliográficos
Autores principales: Anzueto, Antonio R., Kostikas, Konstantinos, Mezzi, Karen, Shen, Steven, Larbig, Michael, Patalano, Francesco, Fogel, Robert, Banerji, Donald, Wedzicha, Jadwiga A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011394/
https://www.ncbi.nlm.nih.gov/pubmed/29925383
http://dx.doi.org/10.1186/s12931-018-0830-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011394/
https://www.ncbi.nlm.nih.gov/pubmed/29925383
http://dx.doi.org/10.1186/s12931-018-0830-z

Ejemplares similares